BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 466 filers reported holding BIO-TECHNE CORP in Q1 2021. The put-call ratio across all filers is 0.87 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $48,534 | -0.2% | 713 | +19.6% | 0.00% | 0.0% |
| Q2 2023 | $48,651 | +149.3% | 596 | +126.6% | 0.00% | +100.0% |
| Q1 2023 | $19,512 | +88.3% | 263 | +110.4% | 0.00% | +100.0% |
| Q4 2022 | $10,360 | +48.0% | 125 | +380.8% | 0.00% | 0.0% |
| Q3 2022 | $7,000 | -22.2% | 26 | +4.0% | 0.00% | 0.0% |
| Q2 2022 | $9,000 | -98.3% | 25 | -98.0% | 0.00% | -97.1% |
| Q1 2022 | $537,000 | -16.2% | 1,240 | 0.0% | 0.03% | -12.8% |
| Q4 2021 | $641,000 | +7.2% | 1,240 | +0.4% | 0.04% | -7.1% |
| Q3 2021 | $598,000 | +7.6% | 1,235 | +0.1% | 0.04% | +13.5% |
| Q2 2021 | $556,000 | +18.0% | 1,234 | 0.0% | 0.04% | +8.8% |
| Q1 2021 | $471,000 | -19.8% | 1,234 | -33.2% | 0.03% | -27.7% |
| Q4 2020 | $587,000 | +524.5% | 1,848 | +385.0% | 0.05% | +487.5% |
| Q3 2020 | $94,000 | -38.2% | 381 | -33.7% | 0.01% | -33.3% |
| Q2 2020 | $152,000 | +42.1% | 575 | +1.8% | 0.01% | +20.0% |
| Q1 2020 | $107,000 | -9.3% | 565 | +4.8% | 0.01% | 0.0% |
| Q4 2019 | $118,000 | +12.4% | 539 | 0.0% | 0.01% | 0.0% |
| Q3 2019 | $105,000 | -6.2% | 539 | +0.2% | 0.01% | -16.7% |
| Q2 2019 | $112,000 | +4.7% | 538 | 0.0% | 0.01% | -7.7% |
| Q1 2019 | $107,000 | +37.2% | 538 | +0.2% | 0.01% | +18.2% |
| Q4 2018 | $78,000 | -29.1% | 537 | 0.0% | 0.01% | -21.4% |
| Q3 2018 | $110,000 | +39.2% | 537 | +0.2% | 0.01% | +27.3% |
| Q2 2018 | $79,000 | +146.9% | 536 | +149.3% | 0.01% | +175.0% |
| Q1 2018 | $32,000 | +14.3% | 215 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $28,000 | – | 215 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ownership Capital B.V. | 972,263 | $308,742,000 | 4.35% |
| Sandhill Capital Partners LLC | 138,864 | $44,096,000 | 4.03% |
| STONE RUN CAPITAL, LLC | 27,350 | $8,685,000 | 3.45% |
| DF DENT & CO INC | 925,823 | $293,995,000 | 3.42% |
| Brown Capital Management | 1,498,233 | $475,764,000 | 3.29% |
| MAIRS & POWER INC | 848,081 | $269,308,000 | 2.99% |
| Summit Creek Advisors LLC | 64,179 | $20,380,000 | 2.62% |
| GENEVA CAPITAL MANAGEMENT LLC | 402,958 | $127,959,000 | 2.17% |
| Aristotle Atlantic Partners, LLC | 86,993 | $27,625,000 | 2.13% |
| CROWN ADVISORS MANAGEMENT, INC. | 8,000 | $2,540,000 | 1.82% |